Michael Paul Gray
CFO & COOMr. Michael Paul Gray, also known as Mike, M.B.A. C.P.A. is Chief Financial Officer and Chief Operating Officer of Upstream Bio, Inc. from March 2024. He was Chief Financial Officer and Chief Operating Officer of Carmot Therapeutics, Inc. from June 2023 to 2024. He brought a wealth of financial expertise and strategic leadership to Carmot. He joined Carmot Therapeutics, Inc. in June 2023. He is responsible for overseeing financial operations including the development and implementation of corporate finance strategies and tactics, leadership of Investor Relations and corporate communications and supporting strategic initiatives and business operations. In addition, Gray leads cross-functional teams that include Business Development, Human Resources, IT and Facilities. He has public-private leadership experience including broad strategic, financial and operating experience in global companies. He was Chief Financial and Chief Operating Officer at Imara, Inc. since April 2019, where he commenced his employment on April 8, 2019. He was a Director of Therapeutics Acquisition Corp since May 2020 to July 2021. He was President and Chief Executive Officer at Arsanis, Inc. now X4 Pharmaceuticals since November 27, 2018 to Mat Mr. Gray was the Chief Financial Officer of Arsanis, Inc. since March 2, 2016 to September 2017 and served as its Director. He served as Chief Operating Officer of Arsanis, Inc. since September 2017 until November 2018. Mr. Gray served as the Chief Business Officer of Arsanis, Inc. since March 2, 2016 until September 2017. Prior to joining Arsanis, Mr. Gray served in various leadership positions from August 2000 through February 2016 at Curis, Inc. Mr. Gray served as the Chief Financial Officer of Curis, Inc. since November December 2006 until February 29, 2016 and served as its Principal Accounting Officer and Secretary. Mr. Gray served as the Chief Business Officer of Curis, Inc. since February 2014 until February 2016. He served as the Chief Operating Officer of Curis Inc. from December 20, 2006 to February 2014. Mr. Gray served as Controller and de Facto Chief Financial Officer of Reprogenesis and was as an audit professional for Ernst & Young, LLP. He served as Senior Director of Finance and Controller of Curis Inc. from August 2000 to December 2003 and also served as its Vice President of Finance since November 27, 2003 until December 2006. From January 1998 to July 2000, Mr. Gray served as Controller at Reprogenesis, Inc. a biotechnology company focused on the development of cell therapy drug candidates and as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a Certified Public Accountant, holds an M.B.A. in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College and has a B.S. in accounting from Bryant College.
Positions
- Company NameUpstream Bio, Inc.Stock CodeUPBPositionCFO & COOColleagues
- ERE. Rand SutherlandCEO & Director
- RCRonald C. RenaudIndependent Chairman of the Board
- ADAaron DeykinChief Medical Officer and Head of Research & Development
- SPStacy PriceChief Technology Officer
- MBMeggan BuckwellDirector of Corporate Communications & Investor Relations
- MKMarcella Kuhlman RuddyIndependent Director
- DBDaniella BeckmanIndependent Director
- ECErez ChimovitsIndependent Director
